The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting this challenge, several newer therapies have made advances in the PsA market in recent years with the availability of the first IL-12/23 inhibitor, the first IL-17 inhibitor, and the first oral PDE4 inhibitor. However, significant opportunity remains for novel mechanisms of action, new oral therapies, and treatments that can produce improved efficacy with decreased safety concerns.
Related Reports
Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next ten years and...
Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020
A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the...
Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (
Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (